Friday, October 31, 2014

Best Insurance Stocks To Invest In Right Now

  What's your dream retirement? NEW YORK (Money Magazine) When is it worth buying a variable universal life policy? -- Christina Bean, Sacramento

Rarely, says Glenn Daily, an insurance consultant in New York City. VUL, he says, is a poor retirement savings vehicle, though often sold as such.

Ultimate Guide to Retirement Getting started401(k)s & company plansInvestingAnnuitiesIRAsSelf-employment plansPensions and benefit plansSocial SecurityInsuranceEstate planningLiving in retirementGetting help

It's useful primarily, he says, in solving estate planning and asset protection problems for wealthy individuals.

VUL mixes permanent insurance with mutual-fund-like tax-deferred investments, building a cash value you can tap (earnings are taxed as income) or borrow against.

Hot India Stocks To Watch For 2015: Cigna Corp (CI)

Cigna Corporation (Cigna), incorporated on November 3, 1981, is a holding company. Cigna is a global health service company, with insurance subsidiaries that are providers of medical, dental, disability, life and accident insurance and related products and services. In the United States, these products and services are offered through employers and other groups, and in selected international markets, Cigna offers supplemental health, life and accident insurance products and international health care coverage and services to businesses, governmental and non-governmental organizations and individuals. The Company also has certain run-off operations, including a Run-off Reinsurance segment. Cigna�� revenues are derived from premiums, fees, mail order pharmacy, other revenues and investment income. Cigna operates in five segments: Health Care, Disability and Life, International, Run-off Reinsurance, and Other Operations, including Corporate-owned Life Insurance. On January 31, 2012, Cigna acquired HealthSpring, Inc. On November 30, 2011, the Company acquired FirstAssist Group Holdings Limited. In August 2012, the Company acquired Great American Supplemental Benefits from American Financial Group, Inc. In January 2013, the Company acquired select Arcadian and Humana Medicare Advantage plans in Arkansas, Oklahoma and Texas. In September 2013, Cigna Corporation completed its acquisition of Alegis Care, a portfolio company of Triton Pacific Capital Partners. Effective September 3, 2013, Cigna Corp acquired Home Physicians Management LLC.

Health Care

Cigna�� Health Care segment (Cigna HealthCare) offers insured and self-insured medical, dental, behavioral health, vision, and prescription drug benefit plans, health advocacy programs and other products and services that may be integrated to provide health care benefit programs. Cigna HealthCare companies offer these products and services in all 50 states, the District of Columbia and the United States Virgin Islands. Cigna offers a ! range of products and services to employers and other groups that sponsor group health plans. With the exception of Health Maintenance Organization (HMO), Medicare, Voluntary and stop loss products, each of Cigna HealthCare�� products is offered with alternative funding options. Cigna may sell multiple products under the same funding arrangement to the same employer. Approximately 85% of the Company�� medical customers are enrolled in self-insured plans, with the remainder split between guaranteed cost and experience-rated insured plans. Approximately 90% of its medical customers are enrolled in self-insured and experience-rated plans. Cigna also offers guaranteed cost medical and dental insurance to individuals. Cigna HealthCare offers a product line of indemnity managed care benefit plans on an insured (guaranteed cost or experience-rated) or self-insured basis. The Network, Network Open Access, and Open Access Plus In-Network products cover only those services provided by Cigna HealthCare participating health care professionals (in-network) and emergency services provided by non-participating health care professionals (out-of-network). The Network point of service (POS), Network POS Open Access and Open Access Plus plans (OAP) cover health care services provided by participating, and non-participating health care professionals.

Cigna HealthCare offers a Preferred Provider Plans (PPO) product line that features a national network. Like Network and Open Access Plus Plans, the PPO product line is offered on an insured (guaranteed cost or experience-rated) or self-insured basis. Cigna HealthCare offers the Cigna Choice Fund suite of products, including Health Reimbursement Accounts (HRA), Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). Cigna HealthCare offers stop loss insurance coverage for self-insured plans. This stop loss coverage reimburses the plan for claims in excess of a predetermined amount, either for individuals (specific) or the entire group (aggregate), ! or both. ! Cigna HealthCare provides Taft-Hartley trusts and other entities access to its national provider network and provides claim re-pricing and other services. Cigna HealthCare�� voluntary medical products are offered to employers with 51 or more eligible employees. As a result of the acquisition of HealthSpring, Cigna operates Medicare Advantage coordinated care plans in 11 states and the District of Columbia. Under the Medicare program, Medicare-eligible beneficiaries may receive health care benefits, including prescription drugs, through a managed care health plan, such as the Company�� coordinated care plans, and The Centers for Medicare and Medicaid Services reimburse the Company pursuant to a risk adjustment payment methodology.

Cigna�� Medicare Part D prescription drug program, Cigna Medicare Rx, provides a number of plan options, as well as service and information support to Medicare and Medicaid eligible customers. Cigna Medicare Rx is available in all 50 states and the District of Columbia. Cigna HealthCare offers medical management, disease management, and other health advocacy services to employers and other plan sponsors. These services are offered to customers covered under Cigna HealthCare administered plans, as well as individuals covered under plans insured and/or administered by competing insurers/third-party administrators. Cigna�� onsite services include more than 75 health centers and the annual administration of more than 400,000 biometric screenings, as well as approximately 2,200 wellness seminars each year. As a result of the acquisition of HealthSpring, Cigna operates three LivingWell Health Centers, where Medicare customers can receive care from physicians, nurse practitioners, nurses, pharmacists, and nurses educators. Cigna arranges for behavioral health care services for customers through its network of participating behavioral health care professionals. Cigna offers behavioral health care case management services, employee assistance programs (EAP), and wor! k/life pr! ograms to employers, Government entities and other groups sponsoring health benefit plans. As of December 31, 2011, Cigna�� behavioral national network had approximately 108,000 access points to psychiatrists, psychologists and clinical social workers and approximately 9,000 facilities and clinics.

Cigna Pharmacy Management offers prescription drug plans to its insured and self-funded customers both in conjunction with its medical products and on a stand-alone basis. With a network of over 62,000 contracted pharmacies, Cigna Pharmacy Management is a pharmacy benefits manager (PBM) offering clinical integration programs, specialty pharmacy solutions and home delivery of prescription medicines. Cigna�� specialty pharmacy outcome management program, TheraCare, manages specialty conditions. TheraCare is coordinated with other Cigna health advocacy programs and all data is captured for analysis and reporting. Cigna Dental Health offers a variety of dental care products, including dental health maintenance organization plans (Dental HMO), dental preferred provider organization (DPPO) plans, dental exclusive provider organization plans, traditional dental indemnity plans and a dental discount program. As of December 31, 2011, Cigna Dental Health customers totaled approximately 10.9 million. Managed dental care products are offered in 38 states for Dental HMO and 43 states and the District of Columbia for Dental PPO through a network of independent health care professionals that have contracted with Cigna Dental Health to provide dental services. Cigna Dental Health customers access care from the dental PPO network in the United States and one of the dental HMO networks in the United States, with approximately 235,500 DPPO-contracted access points (approximately 92,000 health care professionals) and approximately 58,000 dental HMO-contracted access points (approximately 16,500 health care professionals).

Disability and Life

Cigna�� Disability and Life segment (Cign! a Disabil! ity and Life) provides insurance products and their related services, such as group long-term and short-term disability insurance, group life insurance and accident and specialty insurance. These products and services are provided by subsidiaries of Cigna Corporation. Cigna Disability and Life markets products in all 50 states, the District of Columbia, Puerto Rico, the United States Virgin Islands and Canada. Cigna Disability and Life also provides assistance to employees in returning to work and assistance to their employers in managing the cost of employee disability. Cigna Disability and Life offers personal accident insurance coverage, which consists primarily of accidental death and dismemberment and travel accident insurance to employers. Group accident insurance may be employer-paid or employee-paid. Cigna Disability and Life also offers specialty insurance services that consist primarily of disability and life, accident, and hospital indemnity products to professional or trade associations and financial institutions.

International

CIGNA�� International segment (CIGNA International) offers supplemental health, life and accident insurance products, as well as international health care products and services. These products and services are provided by subsidiaries of Cigna Corporation, including foreign operating entities. Cigna International provides employers, affinity groups and individuals with local and global health care and related financial protection programs. Supplemental health products provide a specified payment for a range of health risks and include personal accident, accidental death, critical illness, hospitalization, travel, dental, cancer and other dread disease coverages. Term life, as well as variable universal life insurance and other savings products are also included in the product portfolio. Cigna International�� supplemental health, life and accident insurance products are offered in South Korea, Taiwan, Indonesia, Hong Kong, the European Un! ion, Chin! a, New Zealand, Thailand and Turkey. In China, Cigna International owns a 50% interest in a joint venture through, which its products and services are offered. Cigna International�� health care businesses primarily consist of products and services to meet the needs of local and multinational companies and organizations and their local and globally mobile employees and dependents. These products and services include insurance and administrative services for medical, dental, vision, life, accidental death and dismemberment, and disability risks. In addition, Cigna International�� health care businesses include products and services, which are primarily provided through group benefits programs to employees of businesses and other organizations in the United Kingdom and Spain. These products and services include medical indemnity insurance coverage, with some offerings having managed care or administrative service aspects.

Run-off Reinsurance

Cigna�� reinsurance segment reinsured guaranteed minimum death benefits (GMDB) (also known as variable annuity death benefits (VADBe)), under certain variable annuities issued by other insurance companies. These variable annuities are investments in mutual funds combined with a death benefit. The Company purchased retrocessional protection that covers approximately 5% of the assumed risks. The Company also maintains a dynamic hedge program. Cigna also reinsured guaranteed minimum income benefits (GMIB) under certain variable annuities issued by other insurance companies. These variable annuities are investments in mutual funds combined with minimum income and death benefits. These products under Cigna�� Run-off Reinsurance segment were sold principally in North America and Europe through a sales force and through intermediaries.

Other Operations

The principal products of the Corporate-owned Life Insurance (COLI) business are permanent insurance contracts sold to corporations to provide coverage on the lives ! of certai! n employees for the purpose of funding employer-paid future benefit obligations. The principal services provided by the COLI business are issuance and administration of the insurance policies. COLI policies provide a death benefit for which Cigna collects fees to cover mortality risk. COLI policies also allow policy owners to borrow against a portion of their cash surrender value.

Advisors' Opinion:
  • [By Monica Gerson]

    Breaking news

    Time Warner Cable (NYSE: TWC) reported a drop in its third-quarter profit. Time Warner Cable's quarterly profit fell to $532 million, or $1.84 per share, from $808 million, or $2.60 per share, in the year-ago period. To read the full news, click here. Synergy Pharmaceuticals (NASDAQ: SGYP) today announced the start of a phase 2 clinical trial to evaluate the safety and efficacy of SP-333, its second-generation GC-C agonist and once-daily oral treatment, in adult patients with opioid-induced constipation (OIC). To read the full news, click here. Cigna (NYSE: CI) reported a 19% rise in its third-quarter earnings and lifted its full-year earnings outlook. To read the full news, click here. Charm Communications (NASDAQ: CHRM) announced today that the special committee of the Company's board of directors, consisting of independent directors Mr. Zhan Wang, Mr. Andrew J. Rickards and Mr. Gang Chen, has retained China Renaissance Securities (Hong Kong) Limited as its financial advisor and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP as its legal advisor. To read the full news, click here.

    Posted-In: Bank of America US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

  • [By DailyFinance Staff]

    Concerns about the political uncertainty in Ukraine caused some volatility in the markets Friday afternoon, with the major indexes making several U-turns ahead of the weekend. The Dow Jones industrial average (^DJI), which had been up by as much as 125 points, briefly dropped into loss territory before rebounding to end 49 points higher. The Standard & Poor's 500 index (^GPSC) edged up 5 points, adding to Thursday's record high, but the Nasdaq composite (^IXIC) lost 10 points. AP/Darko VojinovicPro-Russian militias have seized local government buildings in Crimea, Ukraine; the unrest there is making investors around the world nervous. February was a great month for investors. All three major averages jumped by about 4 percent. UnitedHealth Group (UNH) led the blue chips, gaining 1½ percent. Other health providers – Aetna (AET), Wellpoint (WLP), Cigna (CI) and Humana (HUM) -- all gained between 1½ and 2 percent. And retail stocks remained active. Target (TGT) added another 3 percent. Best Buy rose 4 percent, and Fred's (FRED), a regional department store chain, jumped 10 percent. But Pier 1 (PIR) fell 5½ percent after lowering its earnings outlook for a second time. That led to a series of brokerage downgrades. Decker Outdoor (DECK) tumbled 12 percent. The maker of footwear brands such as Ugg and Teva issued a weak outlook. And apparel maker Lululemon (LULU) fell 5-percent on negative comments from Credit Suisse. It seems as though there are always some big movers in the drug and biotech sectors – and that was certainly the case today. GW Pharmaceuticals (GWPH) rose 2 percent after the FDA granted orphan status to its drug to treat a rare form of childhood epilepsy. But most of the action was on the downside. Endologix (ELGX) slid 24 percent after forecasting lower revenue growth. Questcor (QCOR) fell 10 percent. It's lost big for three straight days amid allegations of questionable business practices. Jazz Pharma

Best Insurance Stocks To Invest In Right Now: Allstate Corp (ALL)

The Allstate Corporation (Allstate), November 5, 1992, is a holding company for Allstate Insurance Company. The Company�� business is conducted principally through Allstate Insurance Company, Allstate Life Insurance Company and their affiliates. It is engaged, principally in the United States, in the property-liability insurance, life insurance, retirement and investment product business. Allstate's primary business is the sale of private passenger auto and homeowners insurance. The Company also sells several other personal property and casualty insurance products, select commercial property and casualty coverages, life insurance, annuities, voluntary accident and health insurance and funding agreements. Allstate primarily distributes its products through exclusive agencies, financial specialists, independent agencies, call centers and the Internet. It conducts its business primarily in the United States. Allstate has four business segments: Allstate Protection, Allstate Financial, Discontinued Lines and Coverages and Corporate and Other. The Company is a personal lines insurer in the United States. Customers can access Allstate products and services, such as auto insurance and homeowners insurance through nearly 12,000 exclusive Allstate agencies and financial representatives in the United States and Canada. In October 2011, the Company acquired Esurance and Answer Financial from White Mountains Insurance Group.

ALLSTATE PROTECTION SEGMENT

In this segment, the Company principally sells private passenger auto and homeowners insurance through agencies and directly through call centers and the Internet. These products are marketed under the Allstate, Encompass and Esurance brand names. The Allstate Protection segment also includes a separate organization called Emerging Businesses, which comprises Business Insurance (commercial products for small business owners), Consumer Household (specialty products including motorcycle, boat, renters and condominium insurance policies), A! llstate Dealer Services (insurance and non-insurance products sold primarily to auto dealers), Allstate Roadside Services (retail and wholesale roadside assistance products) and Ivantage (insurance agency). The Company also participates in the involuntary or shared private passenger auto insurance business in order to maintain its licenses to do business in many states. In some states, Allstate exclusive agencies offer non-proprietary property insurance products. Allstate brand auto and homeowners insurance products are sold primarily through Allstate exclusive agencies and serve customers who prefer local personal advice and service and are brand-sensitive. In most states, customers can also purchase certain Allstate brand personal insurance products, and obtain service, directly through call centers and the Internet.

During the year ended December 31, 2011, total Allstate Protection premiums written were $25.98 billion. Its broad-based network of approximately 10,000 Allstate exclusive agencies in approximately 9,700 locations in the United States produced approximately 86% of the Allstate Protection segment's written premiums in 2011. It provides personal property and casualty insurance products through independent agencies in the United States. Additionally, Allstate distribution, through brokering arrangements, offers non-proprietary products to consumers when an Allstate product is not available.

ALLSTATE FINANCIAL SEGMENT

Allstate Financial segment provides life insurance, retirement and investment products, and voluntary accident and health insurance products. Its principal products are interest-sensitive, traditional and variable life insurance; fixed annuities, including deferred and immediate; and voluntary accident and health insurance. Its institutional products consist of funding agreements sold to unaffiliated trusts that use them to back medium-term notes issued to institutional and individual investors. Banking products and services were offered to! customer! s through the Allstate Bank through September 2011. In 2011, after receiving regulatory approval to voluntarily dissolve, Allstate Bank ceased operations.

The Company sells Allstate Financial products to individuals through multiple intermediary distribution channels, including Allstate exclusive agencies and exclusive financial specialists, independent agents, specialized structured settlement brokers and directly through call centers and the Internet. The Company sells products through independent agents affiliated with approximately 125 master brokerage agencies. Independent workplace enrolling agents and Allstate exclusive agencies also sell its voluntary accident and health insurance products primarily to employees of unaffiliated businesses. Its mortgage loan portfolio, which is primarily held in the Allstate Financial portfolio, totaled $7.14 billion as of December 31, 2011

Allstate Financial, through several companies, is authorized to sell life insurance and retirement products in all 50 states, the District of Columbia, Puerto Rico, the United States, Virgin Islands and Guam. Allstate Financial distributes its products to individuals through multiple distribution channels, including Allstate exclusive agencies and exclusive financial specialists, independent agents (including master brokerage agencies and workplace enrolling agents), specialized structured settlement brokers and directly through call centers and the Internet.

OTHER BUSINESS SEGMENTS

The Company�� Corporate and Other segment consistsof holding company activities and certain non-insurance operations. It�� Discontinued Lines and Coverages segment includes results from insurance coverage that it no longer writes and results for certain commercial and other businesses in run-off. Its exposure to asbestos, environmental and other discontinued lines claims is presented in the segment. The segment also includes the historical results of the commercial and reinsurance businesses ! sold in 1! 996.

Advisors' Opinion:
  • [By Jessica Alling]

    Insurance operating income jumped 28% compared to 2012, while investment income was relatively flat. The company has been working on both its underwriting practices and risk selection. And though the flat nature of its investment income may seem disappointing, all of the players in the insurance market have been dealing with pressure from the low interest rates. So the investment income generated by AIG is sign of strength in a difficult environment, with both positive returns from higher securities values and alternative investments. Competitor Allstate (NYSE: ALL  ) noted in its earnings report Wednesday that it was moving into more cash-generating investments that would ultimately lead to lower investment income in the future. AIG hasn't made the same move, and may end up benefiting from the decision to hold firm.

Best Insurance Stocks To Invest In Right Now: Aspen Insurance Holdings Ltd (AHL)

Aspen Insurance Holdings Limited (Aspen Holdings), incorporated on May 23, 2002, is a holding company. The Company conducts insurance and reinsurance business through its subsidiaries in three jurisdictions: Aspen Insurance UK Limited (Aspen U.K.) and Aspen Underwriting Limited (AUL), corporate member of Syndicate 4711 at Lloyd�� of London (United Kingdom), Aspen Bermuda Limited (Aspen Bermuda) and Aspen Specialty Insurance Company (Aspen Specialty) and Aspen American Insurance Company (AAIC). Aspen U.K. also has branches in Paris (France), Zurich (Switzerland), Dublin (Ireland), Cologne (Germany), Singapore, Australia and Canada. It operates in the global markets for property and casualty insurance and reinsurance. It manages its insurance and reinsurance businesses as two distinct underwriting segments, Aspen Insurance and Aspen Reinsurance (Aspen Re), to serve its global customer base. Its insurance segment is consisted of property, casualty, marine, energy and transportation insurance and financial and professional lines insurance. Its reinsurance segment is consisted of property reinsurance (catastrophe and other), casualty reinsurance and specialty reinsurance. In April 2013, the reinsurance segment of the Company announced the formation of a new division, Aspen Capital Markets.

In the Company�� insurance segment, property, casualty and financial and professional lines insurance business is written in the London Market through Aspen U.K. and in the United States through Aspen Specialty and AAIC. Its marine, energy and transportation insurance business is written through Aspen U.K. and AUL, which is the corporate member of Syndicate 4711 at Lloyd�� of London (Lloyd��), managed by Aspen Managing Agency Limited (AMAL). It also writes casualty business through AUL. In reinsurance, property reinsurance business is assumed by Aspen Bermuda and Aspen U.K. The property reinsurance business written in the United States is written by Aspen Re America and ARA-CA as reinsurance intermed! iaries with offices in Connecticut, Illinois, Florida, New York, Georgia and California. The business written in the United States is produced by Aspen Re America.

Reinsurance

The Company�� reinsurance segment consists of property catastrophe reinsurance, other property reinsurance (risk excess, pro rata, risk solutions and facultative), casualty reinsurance (the United States treaty, international treaty and global facultative) and specialty reinsurance (credit and surety, structured, agriculture and specialty). Property catastrophe reinsurance is written on a treaty excess of loss basis where it provides protection to an insurer for an agreed portion of the total losses from a single event in excess of a specified loss amount. In the event of a loss, contracts provide for coverage of a second occurrence following the payment of a premium to reinstate the coverage under the contract, which is referred to as a reinstatement premium. The coverage provided under excess of loss reinsurance contracts may be on a global basis or limited in scope to selected regions or geographical areas.

Other property reinsurance includes risk excess of loss and proportional treaty reinsurance, facultative or single risk reinsurance and its risk solutions business. Risk excess of loss reinsurance provides coverage to a reinsured where it experiences a loss in excess of its retention level on a single risk basis. Proportional contracts involve close client relationships, including regular audits of the cedants��data. Its risk solutions business writes property insurance risks for a select group of the United States program managers. Casualty reinsurance is written on an excess of loss, proportional and facultative basis and consists of the United States treaty, international treaty and casualty facultative. Its United States treaty business consists of exposures to workers��compensation (including catastrophe), medical malpractice, general liability, auto liability, professional l! iability ! and excess liability, including umbrella liability. Its international treaty business reinsures exposures respect to general liability, auto liability, professional liability, workers��compensation and excess liability.

Specialty reinsurance is written on an excess of loss and proportional basis and consists of credit and surety reinsurance, structured risks, agriculture reinsurance and other specialty lines. Its credit and surety reinsurance business consists of trade credit reinsurance, international surety reinsurance (mainly European, Japanese and Latin American risks and excluding the United States) and a political risks portfolio. Its agricultural reinsurance business is written on a treaty basis covering crop and multi-peril business. Other specialty lines include reinsurance treaties and some insurance policies covering policyholders��interests in marine, energy, liability aviation, space, contingency, terrorism, nuclear, personal accident and crop reinsurance. A percentage of the property reinsurance contracts it writes exclude coverage for losses arising from the peril of terrorism. These contracts exclude coverage protecting against nuclear, biological or chemical attack.

The Company competes Arch Capital Group Ltd., Axis Capital Holdings Limited (Axis), Endurance Specialty Holdings Ltd. (Endurance), Everest Re Group Limited, Lancashire Holdings Limited, Montpelier Re Holdings Limited, PartnerRe Ltd., Platinum Underwriters Holdings Ltd., Renaissance Re Holdings Ltd., Validus Holdings Ltd., XL Capital Ltd. (XL) and various Lloyd�� syndicates.

Insurance

The Company�� insurance segment consists of property insurance, casualty insurance, marine, energy and transportation insurance and financial and professional lines insurance. Its property insurance line comprises the United Kingdom commercial property and construction business and the United States property business. Property insurance provides physical damage and business interruption! coverage! for losses arising from weather, fire, theft and other causes. The United States commercial property team covers mercantile, manufacturing, municipal and commercial real estate business. The United States property also includes its program business, which writes property insurance risks for a select group of the United States program managers. The United Kingdom commercial team�� client base is predominantly the United Kingdom institutional property owners, middle market corporates and public sector clients.

The Company�� casualty insurance line comprises commercial liability, global excess casualty, the United States casualty insurance and environmental liability, written on a primary, quota share and facultative basis. Commercial liability is written in the United Kingdom and provides employers��liability coverage and public liability coverage for insureds domiciled in the United Kingdom and Ireland. The global excess casualty line comprises risk-managed insureds globally and covers risks at points, including general liability, commercial and residential construction liability, life science, railroads, trucking, product and public liability and associated types of cover found in general liability policies in the global insurance market. The United States casualty account consists of lines written within the general liability and umbrella liability insurance sectors. Coverage on its general liability line is offered on those risks that are miscellaneous, products liability, contractors (general contractors and artisans), real estate and retail risks and other general liability business. The United States environmental account provides contractors��pollution liability and pollution legal liability across industry segments that have environmental regulatory drivers and contractual requirements for coverage, including real estate and public entities, contractors and engineers, energy contractors and environmental contractors and consultants. The business is written in both the primar! y and exc! ess insurance markets.

The Company�� marine, energy and transportation insurance line comprises marine, energy and construction (M.E.C.) liability, energy physical damage, marine hull, specie, inland marine and ocean risks and aviation, written on a primary, quota share and facultative basis. The M.E.C. liability business includes marine liability cover related to the liabilities of ship-owners and port operators, including reinsurance of Protection and Indemnity Clubs (P&I Clubs). It also provides liability cover for companies in the oil and gas sector, both onshore and offshore and in the power generation and the United States commercial construction sectors. Energy physical damage provides insurance cover against physical damage losses in addition to Operators Extra Expenses (OEE) for companies operating in the oil and gas exploration and production sector. The marine hull team insures physical damage for ships (including war and associated perils) and related marine assets. The specie business line focuses on the insurance of property items on an all risks basis, including fine art, general and bank related specie, jewelers��block and armored car. The inland marine and ocean cargo team writes business covering builders��construction risk, contractors��equipment, transportation and ocean cargo risks in addition to exhibition, fine arts and museums insurance.

The aviation team writes physical damage insurance on hulls and spares (including war and associated perils) and comprehensive legal liability for airlines, smaller operators of airline equipment, airports and associated business and non-critical component part manufacturers. It also provides aviation hull deductible cover. Its financial and professional lines comprise financial institutions, professional liability (including management and technology liability), financial and political risks and the United States surety risks, written on a primary, quota share and facultative basis. Its financial institutions ! business ! is written on both a primary and excess of loss basis and consists of professional liability, crime insurance and directors��and officers��(D&O) cover. It covers financial institutions, including commercial and investment banks, asset managers, insurance companies, stockbrokers and insureds with hybrid business models. Its professional liability business is written out of the United States (including Errors and Omissions (E&O)), the United Kingdom and Switzerland and is written on both a primary and excess of loss basis.

The Company insures a range of professions, including lawyers, accountants, architects and engineers. Its management and technology liability teams write on both a primary and excess basis D&O insurance, technology-related policies in the areas of network privacy, misuse of data and cyber liability and warranty and indemnity insurance in connection with, or to facilitate, corporate transactions. The financial and political risks team writes business covering the credit/default risk on a range of project and trade transactions, as well as political risks, terrorism (including multi-year war on land cover), piracy and kidnap and ransom (K&R). It writes financial and political risks globally but with concentrations in a range of countries, such as Russia, China, Brazil, the Netherlands and United States. Its surety team writes commercial surety risks, admiralty bonds and similar maritime undertakings, including federal and public official bonds, license and permits and fiduciary and miscellaneous bonds and privately owned companies in the United States.

Advisors' Opinion:
  • [By Jake L'Ecuyer]

    Equities Trading UP
    Aspen Insurance Holdings (NYSE: AHL) shares shot up 11.33 percent to $43.83 after Endurance Specialty Holdings (NYSE: ENH) offered to buy Aspen Insurance for $47.50 per share in a cash and stock deal.

  • [By Sally Jones] % over 12 months, Aspen Insurance Holdings Ltd. has a market cap of $2.63 billion; its shares were traded at around $40.06 with a P/E ratio of 13.50. The dividend yield is 1.80%.

    The GuruFocus analysis for AHL shows six warning signs.

    Track historical share pricing, revenue and net income:

    [ Enlarge Image ]

    Guru Action: As of Sept. 30, 2013, Arnold Schneider reduced his position by 89.42%, selling 109,081 shares at an average price of $36.77, for a gain of 8.9%.

    Over five quarters, Schneider has averaged a 28% gain on 166,209 shares bought at an average price of $31.34 per share. He gained 8% selling 153,305 shares at an average price of $37.03 per share.

    Guru Action: As of Sept. 30, 2013, Jim Simons increased his position by 387.47%, buying 501,000 shares at an average price of $36.77, for a gain of 8.9%. His current shares are 630,300.

    Over five years, Simons has sold out three times. He has averaged a 15% gain on 876,900 shares bought at an average price of $34.82 per share. He gained 13% on 246,600 shares sold at an average price of $35.35 per share.

    Guru Action: As of Sept. 30, 2013, Steven Cohen increased his position by 190.15%, buying 15,037 shares at an average price of $36.77, for a gain of 8.9%. His current shares are 22,945.

    Cohen has averaged an 18% gain on 36,658 shares bought at an average price of $33.98 per share. He gained 22% on 13,713 shares sold at an average price of $32.85 per share.

    Guru Action: As of Sept. 30, 2013, top guru stakeholder David Einhorn reduced his position by 36.93%, selling 1,451,581 shares at an average price of $36.77, for a gain of 8.6%. This trade impacts his portfolio by -1%. His current shares are 2,478,935 or 3.67% of shares outstanding.

    Over five years, Einhorn has averaged a 67% gain on 5,700,182 shares bought at an average price of $23.88 per share. He gained 15% on 3,221,247 shares sold at an average price of $34.57 per share.

    Here�

  • [By Anna Prior]

    Aspen Insurance Holdings Ltd.(AHL) said it expects second-quarter operating earnings above Wall Street projections, citing “the continued excellent performance across our businesses.”

Best Insurance Stocks To Invest In Right Now: Kemper Corp (KMPR)

Kemper Corporation (Kemper), formerly Unitrin, Inc., incorporated in 1990, is a diversified insurance holding company, with subsidiaries that provide life, health, automobile, homeowners and other insurance products to individuals and small businesses. The Company is engaged, through its subsidiaries, in the property and casualty insurance, life and health insurance and automobile finance businesses. The Company conducts its operations through four operating segments: Kemper Preferred (Preferred), Unitrin Specialty (Specialty), Unitrin Direct (Direct) and Life and Health Insurance. On September 14, 2011, its subsidiary, Fireside Bank sold its loan portfolio to a subsidiary of Consumer Portfolio Services, Inc.

Property and Casualty Insurance Business

The Company's property and casualty insurance business operations are primarily conducted through the Preferred, Specialty and Direct segments. In addition, the Life and Health Insurance segment�� career agents also sell property insurance to its customers. Its insurance subsidiaries operating in the Preferred, Specialty and Direct segments provide automobile, homeowners, fire, and other types of property and casualty insurance to individuals and commercial automobile insurance to businesses. During the year ended December 31, 2011, automobile insurance in these segments accounted for 54% of its consolidated insurance premiums earned from continuing operations, and 47% of its consolidated revenues from continuing operations. During 2011, homeowners insurance in these segments accounted for 14% of its consolidated insurance premiums earned from continuing operations, and 11% of its consolidated revenues from continuing operations.

Preferred and Specialty segments distribute their products through independent agents who are paid commissions for their services. Direct segment distributes its products directly to consumers and through employer-sponsored voluntary benefit programs and other affinity relationships.! Preferred, based in Jacksonville, Florida, conducts business in 38 states and the District of Columbia. During 2011, the states, which provided over half of the premium revenues in Preferred segment included New York (19%), California (12%), North Carolina (13%) and Texas (10%). Preferred segment primarily sells preferred and standard risk automobile and homeowners insurance. During 2011, Preferred�� insurance products accounted for 53% of the aggregate insurance premium revenues of the Company�� property and casualty insurance business. Its products are marketed by approximately 2,700 independent insurance agents. Specialty, based in Dallas, Texas, conducts business in 21 states, principally in the southwest and western United States. During 2011, the states, which provided more than three-fourths of the premium revenues in Specialty segment included California (42%), Texas (18%), Washington (8%), Louisiana (4%) and Oregon (3%). Specialty provides personal and commercial automobile insurance. During 2011, Specialty�� insurance products accounted for 28% of the aggregate insurance premium revenues of the Company�� property and casualty insurance business. Specialty�� products are marketed through approximately 8,000 independent agents and brokers.

Direct, based in Chicago, Illinois, markets personal automobile, homeowners and renters insurance through a range of direct-to-consumer Websites, including its own Websites, marketing partners, employer and other affinity-sponsored relationships. The Direct segment�� automobile insurance products are available in 48 states and the District of Columbia. During 2011, the states, which provided approximately two-thirds of the premium revenues in Unitrin Direct segment included Florida (12%), New York (15%), California (10%), Texas (5%), Connecticut (5%), Michigan (8%), Pennsylvania (5%) and Georgia (5%). During 2011, Direct�� insurance products accounted for 14% of the aggregate insurance premium revenues of its property and casualty i! nsurance ! business.. Direct also offers homeowners and renters insurance across 47states and the District of Columbia, complementing its direct automobile insurance business. The Company manages its exposure to catastrophes and other natural disasters through a combination of geographical diversification, restrictions on the amount and location of new business production in certain regions, and reinsurance. To limit its exposures to catastrophic events, the Company maintains various primary catastrophe reinsurance programs for its property and casualty insurance businesses.

Life and Health Insurance Business

The Company�� Life and Health Insurance segment consists of Kemper�� wholly owned subsidiaries, United Insurance Company of America (United Insurance), The Reliable Life Insurance Company (Reliable), Union National Life Insurance Company (Union National Life), Mutual Savings Life Insurance Company (Mutual Savings Life), United Casualty Insurance Company of America (United Casualty), Union National Fire Insurance Company (Union National Fire), Mutual Savings Fire Insurance Company (Mutual Savings Fire) and Reserve National Insurance Company (Reserve National). As discussed below, United Insurance, Reliable, Union National Life, Mutual Savings Life, United Casualty, Union National Fire and Mutual Savings Fire (the Kemper Home Service Companies) distribute their products through a network of employee, or career, agents. Reserve National distributes its products through a network of exclusive independent agents. Both these career agents and independent agents are paid commissions for their services. During 2011, the states, which provided approximately two-thirds of the Life and Health Insurance segment�� premium revenues included Texas (21%), Louisiana (11%), Alabama (7%), Mississippi (6%), Illinois (4%), Florida (4%), Georgia (4%), Missouri (4%), and North Carolina (4%). During 2011, life insurance accounted for 18% of the Company�� consolidated insurance premiums earned from ! continuing! operations, and 16% of its consolidated revenues from continuing operations.

The Kemper Home Service Companies, based in St. Louis, Missouri, focus on providing individual life and health insurance products to customers of modest incomes who desire basic protection for themselves and their families. Their product is ordinary life insurance, including permanent and term insurance. Face amounts of these policies are lower than those of policies sold to higher income customers by other companies in the life insurance industry. Approximately 79% of the Life and Health Insurance segment�� premium revenues are generated by the Kemper Home Service Companies. The Life and Health Insurance segment�� career agents also distribute certain property insurance products. Reserve National, based in Oklahoma City, Oklahoma, is licensed in 35 states throughout the south, southwest and midwest, and specializes in the sale of Medicare Supplement insurance and limited health insurance coverages, such as fixed indemnity, dental and vision, and accident-only plans, primarily to individuals in rural areas where access to a multitude of health plan options is less prevalent.

The Company's life and health insurance companies utilize reinsurance arrangements. Included among the segment�� reinsurance arrangements is excess of loss reinsurance coverage specifically designed to protect against losses arising from catastrophic events under the property insurance policies distributed by the Kemper Home Service Companies��agents and written by Kemper�� subsidiaries, United Casualty, Union National Fire and Mutual Savings Fire, and reinsured by Kemper�� subsidiary, Trinity Universal Insurance Company (Trinity), or written by Capitol County Mutual Fire Insurance Company (Capitol), a mutual insurance company owned by its policyholders, and its subsidiary, Old Reliable Casualty Company (ORCC), and reinsured by Trinity.

Advisors' Opinion:
  • [By Rich Duprey]

    The property and casualty business of insurance company Kemper� (NYSE: KMPR  ) has a new bean counter.

    On Monday, the Chicago-based insurance company�announced�that Elizabeth "Libbie" Bock�will take on the role of CFO for the P&C division, where she would be�responsible for all aspects of operations, reporting, control, planning and analysis, financial management, and competitive analysis.

Best Insurance Stocks To Invest In Right Now: Muenchener Rueckversicherungs Gesellschaft AG in Muenchen (MUV2)

Muenchener Rueckversicherungs Gesellschaft AG in Muenchen is a Germany-based holding company engaged in reinsurance and insurance business fields. The Company diversifies its operations into reinsurance, primary insurance, Munich Health and Asset management. The Reinsurance business comprises five divisions: Life; Europe and Latin America; Germany, Asia Pacific and Africa; Special and Financial Risks, and Global Clients and North America. The business covers a range of products from traditional reinsurance products to solutions for risk assumption. The Company's primary insurance activities are combined into the ERGO Insurance Group (ERGO) and offers direct insurance, life, property-casualty, health, legal expenses and travel insurance products. It covers the Company's international health reinsurance business and health primary insurance outside Germany and engages the risk management services. The Asset management business handles the investment activities of Munich Re and ERGO. Advisors' Opinion:
  • [By Jonathan Morgan]

    Munich Re (MUV2), the world�� biggest reinsurer, dropped 4.9 percent to 145.25 euros after it said second-quarter profit fell 35 percent, missing analysts��estimates, as claims arising from natural disasters rose. Net income dropped to 529 million euros from 808 million euros a year earlier, trailing the 557.1 million-euro average estimate of analysts surveyed by Bloomberg.

Thursday, October 30, 2014

Top 5 Restaurant Stocks For 2015

Top 5 Restaurant Stocks For 2015: Blue Water Global Group Inc (BLUU)

Blue Water Global Group, Inc. (Blue Water), incorporated on March 3, 2011, is a development-stage company. The Company focuses on developing a chain of casual dining restaurants in tourist destinations throughout the Caribbean region. The Company's initial restaurant is going to be called Blue Water Bar & Grill and will be located in St. Maarten, Dutch West Indies.

As of February 7, 2013, the Company did not operate any restaurant properties, and did not have any ownership or leaseholds in any restaurant properties. As of February 7, 2013, the Company did not have any ownership or leaseholds in any restaurant properties.

Advisors' Opinion:
  • [By Peter Graham]

    Small cap stocks Naturalnano Inc (OTCMKTS: NNAN), Global Payout, Inc (OTCMKTS: GOHE) and Blue Water Global Group Inc (OTCBB: BLUU) were either jumping higher or diving lower yesterday. To complicate matters for investors, two of these small cap stocks have been subjects of disclosures about paid promotion or investor relation campaigns. So what will these three small caps do for the rest of this week? Here is a closer look to help you decide on a trading or investing strategy:

  • [By Peter Graham]

    Last Friday, small cap Digital Brand Media & Marketing Group Inc (OTCMKTS: DBMM) surged 22.22% while Blue Water Global Group Inc (OTCBB: BLUU) sank 18.42% and Medina International Holdings, Inc (OTCMKTS: MIHI) sank 50%. However, one of these small caps (Blue Water Global Group) appears to be reversing course in early morning trading today. So with it and the rest of these small cap stocks either sink or swim in trading this week? Here is a closer look to help you decide on an investing or trading strategy:

  • source from Top Stocks For 2015:http://ww! w.topstocksblog.com/top-5-restaurant-stocks-for-2015.html

Wednesday, October 29, 2014

Top 10 Net Payout Yield Companies To Invest In 2015

Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output. That's because earnings are very often less trustworthy than cash flow, since earnings are more open to manipulation based on dubious judgment calls.

Earnings' unreliability is one of the reasons Foolish investors often flip straight past the income statement to check the cash flow statement. In general, by taking a close look at the cash moving in and out of the business, you can better understand whether the last batch of earnings brought money into the company, or merely disguised a cash gusher with a pretty headline.

Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Derma Sciences (Nasdaq: DSCI  ) , whose recent revenue and earnings are plotted below.

Top 10 Net Payout Yield Companies To Invest In 2015: Ferro Corporation (FOE)

Ferro Corporation, together with its subsidiaries, produces and sells specialty materials and chemicals in the United States and internationally. It operates in six segments: Performance Coatings, Electronic Materials, Color and Glass Performance Materials, Polymer Additives, Specialty Plastics, and Pharmaceuticals. The company provides electronic, color, and glass materials, including conductive metal powders, polishing materials, glazes, enamels, pigments, decoration colors, and other performance materials. It also offers polymer and ceramic engineered materials, such as polymer additives, engineered plastic compounds, pigment dispersions, glazes, frits, porcelain enamel, pigments, inks, and high-potency pharmaceutical active ingredients. The company provides its products for a range of applications in various markets, such as appliances, automobiles, building and renovation, electronics, household furnishings, industrial products, packaging, and pharmaceuticals. The com pany sells its products to manufacturers of ceramic tile, major appliances, construction materials, automobile parts, glass, bottles, vinyl flooring and wall coverings, and pharmaceuticals directly, as well as through agents and distributors. Ferro Corporation was founded in 1919 and is headquartered in Mayfield Heights, Ohio.

Advisors' Opinion:
  • [By alicet236]

    President and CEO of Ferro Corp (FOE) Peter T. Thomas bought 20,000 shares on Aug. 7, 2013 at an average price of $6.8. The total transaction amount was $136,000.

Top 10 Net Payout Yield Companies To Invest In 2015: Omeros Corporation(OMER)

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. Its product candidates are derived from its proprietary PharmacoSurgery platform that is designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The company?s lead PharmacoSurgery product candidates include OMS103HP, a Phase 3 clinical program evaluated for OMS103HP?s safety and ability to improve postoperative joint function and reduce pain following arthroscopic partial meniscectomy surgery, and arthroscopic anterior cruciate ligament; OMS302, a Phase 2b clinical trial completed product candidate for use during ophthalmological procedures, including cataract and other lens replacement surgery; and OMS201, a Phase 1/Phase 2 clinical trial completed program for use durin g urological surgery. It also engages in developing proprietary compositions that comprise peroxisome proliferator-activated receptor gamma agonists for the treatment and prevention of addiction to substances of abuse. The company?s pipeline of preclinical product development programs includes Plasmin for Surgical and traumatic bleeding; PDE7 for addictions and compulsive disorders, and movement disorders; MASP-2 for macular degeneration, ischemia-reperfusion injury, transplant surgery, and radiation injury; and PDE10 for Schizophrenia. Omeros Corporation was founded in 1994 and is based in Seattle, Washington.

Advisors' Opinion:
  • [By John Udovich]

    Small cap orphan drug stocks Zalicus Inc (NASDAQ: ZLCS), Omeros Corporation (NASDAQ: OMER) and Viropharma Inc (NASDAQ: VPHM) have been active lately thanks to good news about their orphan drug treatments. In case you aren�� familiar with the term, orphan drug designation by the FDA is granted for drugs targeting conditions affecting 200,000 or fewer US patients annually that are expected to provide significant therapeutic advantage over existing treatments. The designation will also qualify companies for benefits across all stages of drug development, such as�accelerated approval processes, seven years of market exclusivity�after marketing approval, tax credits on�any US�clinical trials, grants and waiver of certain administrative fees.

  • [By John Udovich]

    Last week had been a busy week for biotech IPOs and follow-on offerings plus news from small cap biotech stocks like Omeros Corporation (NASDAQ: OMER), Argos Therapeutics Inc (NASDAQ: ARGS), Revance Therapeutics Inc (NASDAQ: RVNC) and TNI BioTech (OTCMKTS: TNIB) that�� worth noting as a new trading week begins:�

  • [By Monica Gerson]

    Omeros (NASDAQ: OMER) shares fell 2.80% to $8.32 in the pre-market trading. Omeros shares have dropped 9.80% over the past 52 weeks, while the S&P 500 index has gained 16.18% in the same period.

Top Financial Companies To Buy For 2015: Prudential Public Limited Company(PUK)

Prudential plc provides retail financial products and services, and asset management services to individuals and businesses in Asia, the United States, and the United Kingdom. It offers savings, protection, investment, and unit-linked products; manages investments across a range of asset classes for internal, retail, and institutional clients; manages onshore mutual funds; and provides retirement planning, consumer and Islamic finance, and health solutions. The company also provides retirement savings and income solutions; variable annuities; fixed and fixed index annuities; term life, universal life, and variable universal life insurance; permanent individual life insurance; and institutional products, such as guaranteed investment contracts, funding agreements, and medium term note funding agreements. In addition, it offers pensions and annuities; investment plans; and car, health, home, travel, and protection insurance policies. Further, Prudential plc provides fund man agement services for individual and institutional clients. The company was founded in 1848 and is based in London, the United Kingdom.

Advisors' Opinion:
  • [By David O��ara]

    Prudential
    Shares in insurer�Prudential� (LSE: PRU  ) (NYSE: PUK  ) are up 51% in the last 12 months. In that time, the FTSE 100 is 16.7% ahead.

  • [By David O��ara]

    Prudential
    Back in January, analysts were forecasting that�Prudential� (LSE: PRU  ) (NYSE: PUK  ) �would make EPS for the year of 77.1 pence per share. Following a series of steady upgrades, that figure is now 83.6 pence.

  • [By Rupert Hargreaves]

    Today, I am looking at�Prudential� (LSE: PRU  ) (NYSE: PUK  ) to determine whether you should consider buying the shares at 1,097p.

Top 10 Net Payout Yield Companies To Invest In 2015: Forest Oil Corporation (FST)

Forest Oil Corporation, an independent oil and gas company, engages in the acquisition, exploration, development, and production of oil, natural gas, and natural gas liquids in the United States. The company primarily has interests in the properties in the Texas Panhandle; the east Texas/north Louisiana; and the Eagle Ford Shale in south Texas. As of December 31, 2011, its total estimated proved oil and gas reserves were approximately 1,904 billion cubic feet equivalent. The company was founded in 1916 and is headquartered in Denver, Colorado with an additional office in Houston, Texas.

Advisors' Opinion:
  • [By Ben Levisohn]

    Forest Oil�(FST) has gained 7.2% to $6.81 after it announced the sale of some Texas assets for $1 billion.

    Lannett Company (LCI) has dropped 12% to $18.41 after the generic drug maker announced a secondary stock offering.

  • [By Mark Hulbert]

    The stocks are C.H. Robinson Worldwide (CHRW) �, a freight-transportation company; chip maker Cirrus Logic (CRUS) �; independent oil company Forest Oil (FST) �; investment bank Greenhill & Co. (GHL) �; Intrepid Potash (IPI) �, a fertilizer company; retailer J.C. Penney (JCP) �; Quest Diagnostics (DGX) �, a medical diagnostic company; Strayer Education (STRA) �, a for-profit college; Tower Group International (TWGP) �, an insurance company; and Windstream Holdings (WIN) �, a rural telecommunications firm.

Top 10 Net Payout Yield Companies To Invest In 2015: Thinspace Technology Inc (THNS)

Thinspace Technology Inc., formerly Vanity Events Holding, Inc., incorporated on November 22, 2006, is a holding company. Utilizing their licensed trademark of America's Cleaning Company, Vanity established a cleaning company offering residential and commercial cleaning services. In October 2012, the Company acquired fineartlender.com. In October 2012, the Company acquired additional URLS, which include Weddinggownlender.com; Suitlender.com and Bridalpartylender.com.

The Company seeks out, licenses, develops, promotes, and brings to market various consumer and commercial products. The Company markets products directly to the consumer and marketplace through one of its own properties www.ThereIsAProductForThat.com.

The Company competes with Rent the Runway, Inc., Rent-A-Center, Inc., Bag, Borrow or Steal, Inc., Aaron��, and Gilt Groupe, Inc.

Advisors' Opinion:
  • [By Peter Graham]

    Last Friday, small cap biotech or tech stocks Amanasu Techno Holdings Corp (OTCMKTS: ANSU), Bio Matrix Scientific Group Inc (OTCMKTS: BMSN) and Thinspace Technology Inc (OTCBB: THNS) surged 44.74%, 42.31% and 14%, respectively, with only one of these small caps appearing to be the subject of some sort of small paid promotions or investor relations campaign. Given the lack of a big pump from promoters or IR people, will these three small caps keep surging or will the tide go out again this week? Here is a quick reality check to help you decide on a trading or investing strategy:

  • [By Peter Graham]

    Small cap tech or media stocks Thinspace Technology Inc (OTCMKTS: THNS), Beamz Interactive Inc (OTCBB: BZIC) and Hannover House Inc (OTCMKTS: HHSE) have been getting some extra attention lately, but it appears that only one of these stocks has been the subject of a paid promotion. Nevertheless, all three stocks have been busy with press releases trying to get the attention of investors or traders. So are these three small cap tech or media stocks worth your attention? Here is a closer look along with a reality check:

    Thinspace Technology Inc (OTCMKTS: THNS) Was Recently Busy With Press Releases

    Small cap Thinspace Technology Inc is a global provider of reliable, scalable and affordable application delivery, virtualization and cloud client technology to public and private sector companies and organizations of all sizes. On Monday, Thinspace Technology Inc rose 2.80% to $0.330 for a market cap of $30.24 million plus THNS is down 82.6% over the past year and down 89.8% over the past five years according to Google Finance.

Top 10 Net Payout Yield Companies To Invest In 2015: Oncothyreon Inc .(ONTY)

Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in two phase III clinical trials for the treatment of non-small cell lung cancer. The company is also developing PX-866, a small molecule that is in phase II trials for various cancer indications. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine; and ONT-701, a pan-inhibitor of the B-cell lymphoma-2 family of anti-apoptotic proteins. The company operates primarily in the United States and Canada. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Advisors' Opinion:
  • [By Lauren Pollock]

    Among the companies with shares expected to actively trade in Wednesday’s session are Mako Surgical Corp.(MAKO), Ascena Retail Group Inc.(ASNA) and Oncothyreon Inc.(ONTY)

Top 10 Net Payout Yield Companies To Invest In 2015: Bayer AG (BAYRY)

Bayer AG is a management holding company. The Company�� business operations are organized into three subgroups: HealthCare, CropScience and MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. Bayer HealthCare is involved in the research, development and manufacture of health products for people and animals. Bayer CropScience is engaged in the crop protection and non-agricultural pest control. Bayer MaterialScience supplies polymers, and develops solution for a range of applications. In November 2009, Bayer MaterialScience acquired the polymer coatings business from Lombard Medical Technologies PLC. On November 2, 2009, it acquired Athenix Corporation. On October 1, 2009, it acquired two dermatology product lines from SkinMedica, Inc., Carlsbad, California, United States. On June 25, 2009, it acquired the remaining 10% interest in Bayer Polymers (Shanghai) Co. Ltd., China. In May 2009, it acquired the remaining 49% interest in Berlimed, s.a., Spain, from Juste s.a. Quimica Farmac茅utica (Juste), and in return sold its 51% interest of Justesa Imagen, s.a., Spain, to Juste. In May 2009, it also sold the Thermoplastics Testing Center, Krefeld, Germany, to Underwriters Laboratories Inc. In March 2010, the Company announced that its Bayer MaterialScience LLC has acquired Artificial Muscle, Inc, a company active in electroactive polymers for the consumer electronics industry.

Bayer HealthCare

The Company researches, develops, manufactures pharmaceutical and medical products. Bayer HealthCare operates in four operating divisions: Animal Health, which is engaged in manufacture of veterinary medicines and grooming products; Bayer Schering Pharma, which is engaged in manufacture of prescription medicines; Consumer Care, which is engaged in the manufacture of over-the-counter medicines and dietary supplements, and Medical Care, which is engaged in manufacture of blood glucose monitoring devices and contrast agent injecti! on systems. Its products for farm animals include Baytril. Its products for companion animals include Advantage/Advantix and Baytril. Its drug discovery in the pharmaceuticals segment focuses on the areas of cardiology, oncology,

women�� healthcare and diagnostic imaging.

Bayer CropScience

CropScience maintains a global network of research and development facilities. In the Crop Protection segment it identifies and develops safe and economically sustainable insecticides, fungicides and herbicides and carries its research projects in areas, such as plant health or stress tolerance. As of December 31, 2009, its active ingredient pipeline of Crop Protection contained 20 development projects, of which 10 was at an advanced stage and 10 at an early stage of development, and an additional 45 projects was undergoing early-stage research. Its operations are structured into six business operations units: four regional Crop Protection units plus the Environmental Science and BioScience units. Its insecticides include Confidor/ Admire, Calypso, Decis, Temik and Oberon. Its fungicides include Antracol, Fandango, Flint/Stratego/Sphere/Twist, Folicur and Previcur Energy. Its herbicides include Atlantis, Basta, Betanal, Fenikan, Hoestar, Husar, MaisTer, Puma. Its seed treatment products include Bariton, Gaucho, Lamarador, Poncho and Raxil.

Bayer MaterialScience

The Company supplies materials, such as polycarbonates and polyurethanes and system solutions for a range of everyday uses. It operates in three business units: Polyurethanes, Polycarbonates, and Coatings, Adhesives and Specialties. Its Coatings, Adhesives, Specialties producst include Desmodur, Bayhydur, Dispercoll and Artwalk. Its Polycarbonates include Makrolon, Makrofol / Bayfol, Fantasia and Bayblend. Its Polyurethanes include Multitec, Baydur, Bayflex, Baypreg and Vulkollan. Its Thermoplastic Polyurethanes include Desmopan / Texin.

Advisors' Opinion:
  • [By Jeff Reeves]

    The Dodge & Cox International Stock Fund (DODFX), one of the top 25 mutual funds by total assets, also has a 30% allocation in Europe. It owns stakes in German conglomerate Bayer (BAYRY) and the U.K. bank HSBC (HBC).

  • [By Sean Williams]

    So what: In midday trading, AVEO and development partner Astellas Pharma reported that the FDA panel had voted 13-1 that Tivozanib had not demonstrated a favorable benefit-to-risk evaluation in treating advanced kidney cancer. AVEO's CEO, Tuan Ha-Ngoc, noted his discouragement with the FDA panels' findings, but plans to work closely with the FDA to improve upon what it felt Tivozanib lacked. If you recall, Tivozanib demonstrated a statistically significant progression-free survival benefit over Onyx Pharmaceuticals (NASDAQ: ONXX  ) and Bayer's (NASDAQOTH: BAYRY  ) Nexavar in trials, but fell short of Nexavar in terms of median overall survival, which perplexed many.

Top 10 Net Payout Yield Companies To Invest In 2015: Constellation Brands Inc (STZ.B)

Constellation Brands, Inc., incorporated on December 4, 1972, is a producer and marketer of beer, wine and spirits with operations in the United States, Canada, Mexico, New Zealand and Italy. The Company�� beer brands include Corona Extra, Corona Light, Modelo Especial, Negra Modelo and Pacifico. Its wine brands consist of Robert Mondavi, Clos du Bois, Kim Crawford, Rex Goliath, Mark West, Franciscan Estate, Ruffino and Jackson-Triggs. The Company�� spirits brands include SVEDKA Vodka and Black Velvet Canadian Whisky. The Company has more than 100 brands in its portfolio, sales in approximately 100 countries and has about 40 facilities.

Beer

The Company imports markets and sells Mexican Beer Brands in all 50 states of the United States, which includes Corona Extra, Corona Light, Modelo Especial, Pacifico, Negra Modelo and Victoria. During the fiscal year ended February 28, 2014 (fiscal 2014), the Company had 15 imported beer brands in the United States. During fiscal 2014, the Company introduced Modelo Especial Chelada, a blend of Modelo Especial with flavors of tomato, salt and lime.

Wine and Spirits

The Company sells a range of wine brands across all categories, such as table wine, sparkling wine and dessert wine in the United States, Canada and New Zealand. Its wine produced in the United States is primarily marketed domestically and in Canada and the United Kingdom. The wine produced in Canada is primarily marketed domestically. Wine produced in New Zealand is primarily marketed in the United States, Canada, Australia, the United Kingdom and domestically. Wine produced in Italy is primarily marketed in the United States, Canada and domestically. In addition, it also exports its wine products to other world markets. Its spirits business, Svedka Vodka is imported from Sweden.

The Company sells its wine brands in the United States, which comprise its United States Focus Brands (Focus Brands) includes Arbor Mist, Inniskillin, Rex Go! liath, Black Box, Kim Crawford, Robert Mondavi, Blackstone, Mark West, Ruffino, Clos du Bois, Mount Veeder, Simi, Estancia, Nobilo, Toasted Head, Franciscan Estate, Ravenswood and Wild Horse. Its spirits brands include Black Velvet Canadian Whisky and Svedka Vodka.

Corporate Operations and Other

The Corporate Operations and Other segment includes corporate-related items, including executive management, corporate development, corporate finance, human resources, internal audit, investor relations, legal, public relations and global information technology.

The Company competes with Anheuser-Busch InBev, MillerCoors, Heineken, E&J Gallo Winery, The Wine Group, Trinchero, Treasury Wine Estates, Deutsch Family Wine & Spirits, Ste. Michelle Wine Estates, Kendall-Jackson, Andrew Peller, Kruger, Pernod Ricard, Lion Nathan, Diageo, Beam, Pernod Ricard, Bacardi and Brown-Forman.

Advisors' Opinion:
  • [By sandyinvestment]

    As the craft beer industry has a considerable measure of room to develop, Boston Beer confronts rivalry from Molson Coors Brewing (TAP) and Constellation Brands (STZ) (STZ.B). Each of the three organizations have had great runs on the Street, however Boston Beer and Constellation Brands have been the greatest outperformers. We should investigate each of them.

Top 10 Net Payout Yield Companies To Invest In 2015: Peregrine Pharmaceuticals Inc.(PPHM)

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the research and development of monoclonal antibodies for the treatment of cancer and viral infections. Its products under development include bavituximab, a phosphatidylserine-targeting antibody, which is in Phase II trials for the treatment of front-line and second-line non-small cell lung cancer (NSCLC), and pancreatic cancer; and Cotara, a DNA/histone-targeting antibody that is in Phase II trial for the treatment of recurrent glioblastoma multiforme. The company is also developing bavituximab in combination with ribavirin, which is in Phase II clinical trial for the treatment of patients with genotype-1 hepatitis C virus infection. In addition, it has investigator-sponsored trial programs that evaluate bavituximab for the treatment of patients with liver cancer, second-line castration resistant prostate cancer, HER-2 negative metastatic breast cancer, and locally advanced or metasta tic NSCLC. Further, the company, through its wholly-owned subsidiary, Avid Bioservices, Inc., provides integrated current Good Manufacturing Practices (cGMP) commercial and clinical manufacturing services in the United States, including contract manufacturing of antibodies, recombinant proteins, and enzymes; cell culture development; process development; and testing of biologics for biopharmaceutical and biotechnology companies under cGMP. It has licensing agreements with the University of Texas Southwestern Medical Center; Merck KGaA; SuperGen, Inc.; and Affitech A/S. Peregrine Pharmaceuticals, Inc. intends to sell its products in the United States and internationally in collaboration with marketing partners or through a direct sales force. The company was founded in 1981 and is based in Tustin, California.

Advisors' Opinion:
  • [By Sean Williams]

    Also gaining double digits on the week was the highly embattled Peregrine Pharmaceuticals (NASDAQ: PPHM  ) which rallied after the FDA approved its late-stage trial design for its second-line non-small-cell lung cancer immunotherapy, Bavituximab. While trial design approvals are rarely big news, it is in this case because mid-stage results for Bavituximab have been all over the place. At first Bavituximab demonstrated a better than doubling in progression-free survival followed weeks later by management's insistence that investors were not to trust the data. A few months later, following a review, we were told to trust the data again. This filing helps relieve some of the confusion surrounding Peregrine's mid-stage results, and hopefully its phase 3 study will be black-and-white obvious as to whether Bavituximab provides a statistically significant benefit.

Top 10 Net Payout Yield Companies To Invest In 2015: NL Industries Inc (NL)

NL Industries, Inc. (NL) is a holding company. The Company operates in the component products industry through NL's majority-owned subsidiary, CompX International Inc. The Company operates in the chemicals industry through its non-controlling interest in Kronos Worldwide, Inc. As of December 31, 2011, it owned 87% interest in CompX International Inc and 30% interest in Kronos Worldwide, Inc. The Company also owns 100% of EWI RE, Inc., an insurance brokerage and risk management services company. In July of 2011, CompX completed the acquisition of an ergonomic component products business.

Component Products-Compx International Inc.

Through the Company�� subsidiary, CompX, it manufactures components that are sold to a variety of industries including office furniture, recreational transportation (including boats), mailboxes, toolboxes, home appliances, banking equipment, vending equipment and computer-related equipment. CompX�� Security Products business, with one manufacturing facility in South Carolina and one in Illinois shared with the Marine Components business, manufactures mechanical and electronic cabinet locks and other locking mechanisms used in a variety of applications including ignition systems, mailboxes, file cabinets, desk drawers, tool storage cabinets, vending and gaming machines, high security medical cabinetry, electrical circuit panels, storage compartments and gas station security. These products include disc tumbler locks, pin tumbler locking mechanisms, and eLock and Stealthlock electronic locks.

CompX�� Furniture Components business, with facilities in Canada and Taiwan, manufactures a line of ball bearing slides and computer keyboard, monitor and central processing unit (CPU) support systems for use in applications, such as file cabinets, desks, computer server racks, wall mounted computer applications, home appliances, tool storage cabinets, imaging equipment, automated teller machines and other applications. These products include I! ntegrated Slide Lock, Ball Lock, Self-Closing Slide, articulating computer keyboard support arms along with the LeverLock keyboard arm, CPU storage devices, flat panel computer monitor support systems and keyboard, monitor and CPU wall mounts.

CompX�� Marine Components business, with a facility in Wisconsin and a facility shared with the Security Products business in Illinois, manufactures and distributes stainless steel exhaust components, gauges, throttle controls, hardware and accessories primarily for performance and ski/wakeboard boats. These products include original equipment and aftermarket stainless steel exhaust headers, exhaust pipes, mufflers and other exhaust components; gauges, such as global positioning system (GPS) speedometers and tachometers; controls, throttles, steering wheels and other billet aluminum accessories, and dash panels, light emitting diode (LED) lighting, rigging and other accessories. CompX operated five manufacturing facilities, as of December 31, 2011, including one facility in Grayslake, Illinois that housed operations relating to Security Products and Marine Components.

Chemicals-Kronos Worldwide, Inc.

Kronos is a global producer and marketer of titanium dioxide pigments (TiO2), a base industrial product used in a range of applications. Kronos, along with its distributors and agents, sells and provides technical services for NL's products to over 4,000 customers in approximately 100 countries with the majority of sales in Europe and North America. TiO2 is a white inorganic pigment used in a range of products. Kronos offers customers a portfolio of products that include over 40 different TiO2 pigment grades. Kronos��major customers include domestic and international paint, plastics, decorative laminate and paper manufacturers. Kronos ships TiO2 to customers in either a powder or slurry form via rail, truck or ocean carrier. Kronos and its agents and distributors primarily sell and provide technical services for Kronos��pr! oducts in! three markets: coatings, plastics and paper.

Kronos��TiO2 is also found in food products, such as candy and confectionaries and in pet foods. In pharmaceuticals, TiO2 is used commonly as a colorant in pill and capsule coatings, as well as in liquid medicines. Kronos owns and operates two ilmenite mines in Norway. Kronos manufactures and sells iron-based chemicals, which are co-products and processed co-products of the sulfate and chloride process TiO2 pigment production. These co-product chemicals are marketed through Kronos��Ecochem division and are primarily used as treatment and conditioning agents for industrial effluents and municipal wastewater, as well as for the manufacture of iron pigments, cement and agricultural products. Kronos manufactures and sells titanium oxychloride and titanyl sulfate. Kronos produces TiO2 in two crystalline forms: rutile and anatase. Rutile TiO2 is manufactured using both a chloride production process and a sulfate production process, whereas anatase TiO2 is only produced using a sulfate production process.

The chloride process is a continuous process, in which chlorine is used to extract rutile TiO2. The sulfate process is a batch process, in which sulfuric acid is used to extract the TiO2 from ilmenite or titanium slag. Kronos operates four TiO2 plants in Europe, which includes one in each of Leverkusen, Germany; Nordenham, Germany; Langerbrugge, Belgium, and Fredrikstad, Norway. In North America, Kronos has a TiO2 plant in Varennes, Quebec, Canada. Kronos produced 550,000 metric tons of TiO, during the year ended December 31, 2011. Kronos and a subsidiary of Huntsman Corporation each hold a 50% interest in a manufacturing joint venture, Louisiana Pigment Company, L.P. (LPC). LPC owns and operates a chloride process TiO2 facility located in Lake Charles, Louisiana.

The Company competes with E.I. du Pont de Nemours & Co., National Titanium Dioxide Company Ltd., Huntsman Corporation, Tronox Incorporated and Sachtleben Chemi! e GmbH. Advisors' Opinion:

  • [By Ben Levisohn]

    Typically, when the chairman of a company dies, its shares drop. That hasn’t been the case for Valhi (VHI), Kronos Worldwide (KRO) and NL Industries (NL), which have all advanced today after Harold Simmons passed away.

  • [By John Udovich]

    Dallas billionaire Harold Simmons died over the weekend with investors sending shares of some of his publically traded companies like Valhi, Inc (NYSE: VHI), Kronos Worldwide, Inc (NYSE: KRO), NL Industries, Inc (NYSE: NL) and�CompX International Inc (NYSEMKT: CIX)to higher levels as they anticipate changes���such as asset sales or spin offs. Harold Simmons was the embodiment of the American dream because he was born during the depths of the Great Depression in Golden, Texas to schoolteacher parents and he spent�his early years living without indoor plumbing or electricity. However and by recognizing�underpriced assets and through the use of massive amounts of leverage (e.g. junk bonds),�he built an empire and�ranked #40 on the 2013 Forbes 400 with a fortune estimated to be worth some $10 billion.

Tuesday, October 28, 2014

Top 10 Biotech Companies To Buy For 2014

The markets have been on a roll this year, as the S&P 500's (SNPINDEX: ^GSPC  ) picked up more than 18% year to date. The health-care sector's moved right along with the index in 2013, as many leading medical stocks have seen shares roar higher and reward investors with stellar gains.

Not every stock's joined the party, however. A small but select group of laggards hasn't been able to break into the green in 2013 -- and three members of the S&P have left investors shaking their heads. In the following video, Motley Fool contributor Dan Carroll takes you through the index's three worst medical stocks of the year and examines whether this trio of laggards can turn things around in the year's second half.

The worst performers on the S&P haven't shown investors any growth this year, but health care -- and biotech stocks in particular -- have long been a hotbed for great growth stories. But picking biotech stocks isn't the only path to market-beating growth: Motley Fool co-founder David Gardner, founder of the world's No. 1 growth-stock newsletter, has developed a unique strategy for uncovering truly wealth-changing stock picks.�He shares that and a few of his favorite growth stock superstars in a special 100% free report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains, and click here for instant access to a whole new game plan of stock picks to help power your portfolio.

Top 5 Information Technology Stocks To Own For 2015: Cellular Dynamics International Inc (ICEL)

Cellular Dynamics International, Inc., incorporated on November 16, 2007, develops and manufactures fully functioning human cells in industrial quantities to precise specifications. The Company�� iCell Operating System (iCell O/S) includes true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). Customers use its iCell O/S products, among other purposes, for drug discovery and screening; to test the safety and efficacy of their small molecule and biologic drug candidates; for stem cell banking; and in researching cellular therapeutics. The Company�� iCell product line includes four different cell types: cardiomyocytes, neurons, hepatocytes and endothelial cells. The Company is actively developing an additional seven different cell types. iCell products are a consumable designed to be used once and then reordered.

The Company manufactures its iCell products from its iPSCs. An iPSC is a cell that has the ability both to replicate indefinitely and to be transformed into any cell type in the human body. The Company�� iCell O/S consists of six products, which include iCell Cardiomyocytes, iCell Neurons, iCell Endothelial Cells, iCell Hepatocytes and MyCell.

Advisors' Opinion:
  • [By John Udovich]

    Stem cells may not be in the news much�as the sector has moved beyond the use of embryotic�ones, but small cap stem cell stocks Cellular Dynamics International Inc (NASDAQ: ICEL), International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX) have been fairly active over the past several trading days as ICEL went public, ISCO raised additional funding and BRTX grabbed more attention:

Top 10 Biotech Companies To Buy For 2014: Intrexon Corp (XON)

Intrexon Corporation, incorporated on April 19, 2004, is engaged in the business of synthetic biology. Using the Company�� suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery.

The Company�� LEAP technology facilitates the automated identification of an individual cell with the highest levels of expression, quality and potency from a population of over 100,000 cells. Its mAbLogix platform complements UltraVector with a library of human antibodies that exceeds 500 million. By immortalizing human tonsils, which consists of lymphatic tissue containing B-cells, its mAbLogix platform creates a B-cell library that can generate antibodies against an almost infinite number of new antigens.

The UltraVector gene design and fabrication platform

The Company�� gene program design platform, which it refer to as UltraVector, is an integrated suite of tools comprising advanced DNA construction technology and components, cellular and protein engineering tools, computational models and statistical methods which facilitate the rapid design, build and testing of complex systems. The UltraVector platform allows the Company to translate gene programs into standard components that can be designed, manufactured and tested in an automated format. This technology enables it to engineer at the cellular level from biological sources.

UltraVector DNA design is computer-automated and ! utilizes a set of defined construction rules to assemble components that are stored in its DNA library. In addition to the number of gene components in its UltraVector library, it is designing and creating enzymatic and regulatory components that provide control over genome integration and gene regulation. Its RheoSwitch Therapeutic System is a three-component transcriptional regulator that provides inducible gene expression. The RheoSwitch Therapeutic System provides the ability to not only express proteins/enzymes of interest, but also the ability to control the level and timing of expression to achieve a biological outcome. Other ongoing programs include its Attsite recombinases, which mediate predictable gene exchange into host cells thereby eliminating many of the difficulties seen with traditional gene insertion.

Cell Systems Informatics

The Company�� Cell systems informatics permits design, as well as testing and learning about new gene targets or product pathways. Its bioinformatics software and database systems for mapping cellular pathways when combined with its genome-scale modeling and experimental data, including, gene expression profiling and protein engineering, enable the Company to optimize selection and development of gene programs and cellular systems for its collaborators. Its computational modeling and simulation platform enables the development of predictive computer models of organisms, from microbes to humans. This platform builds virtual cells from their basic molecular components, and can simulate the activity of the cell�� complete reaction network.

The Company is designing proteins with post-translational modifications. It is also working to develop enzyme inhibitors and fusion proteins for a variety of applications in human and animal therapeutics. Its protein engineering may utilize one or more of its technologies to obtain catalysis activitiesits component library, the generation of component variants sequence, evolutionary analy! sis and s! tructure-based sequence alignment, computer-aided drug discovery, de novo, or synthesized or generated, and comparative protein modeling, molecular dynamics simulation and free energy analysis, antibody design and humanization, antigenicity prediction, protein pharmacokinetics optimization, and/or in silico support of enzyme engineeringand quantitative structure-function relationships with machine learning algorithms to optimize, facilitate and prioritize protein variant libraries for the advancement of its collaborators.

LEAP-cell identification and selection

The Company�� Laser-Enabled Analysis and Processing technology (LEAP), is an instrument that merges semiconductor manufacturing technologies for cell processing applications to provide high levels of control and scale to cell purification and stem cell culture management. The LEAP platform can identify and purify cells of interest from large libraries of cells created by its UltraVector and bioinformatics technologies using a laser-based purification process, thereby providing a mechanism of testing the degree of protein expression in genetically modified cells, as well as means to learn from the genetic building process.

mAbLogix- antibody discovery

The Company�� mAbLogix antibody discovery platform, or mAbLogix platform, enables production of B-cell libraries for discovery of antibodies. The mAbLogix platform permits antigen targeting using fully human monoclonal and polyclonal antibodies. Its mAbLogix antibody discovery process consists of two major activities: the build of human B-cell libraries expressing a large number of antibodies, and the testing of these libraries based on an analysis of B-cells that express antibodies in response to a chosen antigen.

The Company competes with AbD SeroTec, Alexion Pharmaceuticals, Inc., XOMA Corporation, Genmab US, Inc., MorphoSys AG, NovImmune SA, Societe Des Systemes Biologiques, Adimab, LLC, ProMab Biotechnologies, Inc., Abpro, Inc.,! AIIM The! rapeutics and Open Monoclonal Technology, Inc.

Advisors' Opinion:
  • [By Ben Levisohn]

    Overvalued companies include MWI Veterinary (MWIV) and�Stericycle (SRCL), while companies with attractive valuations include Cardinal Health (CAH), Selected Medical (SEM). He’s not a fan of Intrexon (XON) but calls�Aratana (PETX) a “hidden gem.”

  • [By John Udovich]

    Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:

  • [By Jon C. Ogg]

    Intrexon Corp. (NYSE: XON) was started as Buy at Mizuho Securities, started as Equal Weight at Barclays and started as Overweight at J.P. Morgan.

    Nokia Corp. (NYSE: NOK) was raised to Hold from Sell at Deutsche Bank, raised to Neutral from Underperform at Credit Suisse and
    Canaccord Genuity raised its price target to $5.50 from $3.30.

Top 10 Biotech Companies To Buy For 2014: Chimerix Inc (CMRX)

Chimerix, Inc., incorporated on April, 07, 2000, is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need. Its lipid technology has given rise to two clinical-stage compounds, CMX001 and CMX157, which have demonstrated the potential for enhanced antiviral activity and safety in convenient, orally administered dosing regimens.

CMX001 is an orally administered drug that utilizes its lipid technology to deliver intracellular concentrations of a potent antiviral compound, cidofovir-diphosphate (CDV-PP). Following oral dosing, CMX001 is absorbed through the gut, remains intact in the plasma, and is readily taken up by and delivered into cells. Once inside cells, CMX001 is converted into CDV-PP, which acts as an alternative substrate in a replicating virus. CMX001 is similar to the drug cidofovir in that both drugs are converted into CDV-PP once inside cells. Although cidofovir is approved for administration in an intravenous formulation, Vistide, it requires a plasma concentration to deliver a therapeutic level of cidofovir into cells and its use is limited due to the risk of kidney damage.

CMX157, Its second clinical stage compound, is an oral nucleotide compound in Phase 1 development for the treatment of human immunodeficiency virus (HIV) infection. In July 2012, the Company granted Merck an exclusive worldwide license to develop and commercialize CMX157 for all human uses. Merck is responsible for all development and marketing activities for CMX157 on a worldwide basis.

Advisors' Opinion:
  • [By Ben Levisohn]

    Biotech companies that are most likely to benefit because they are “Ahead in clinical development and/or have established relationships with [the Biomedical Advanced Research and Development Authority, or] BARDA which may facilitate getting a contract” include GlaxoSmithKline (GSK), NewLink Genetics (NLNK), Johnson & Johnson (JNJ) and Chimerix (CMRX). Kantor includes Tekmira�(TKMR) and Sarepta (SRPT) among “companies with viable programs” that are “moving forward and likely to attract additional funding.”

Top 10 Biotech Companies To Buy For 2014: Protalix Biotherapeutics Inc (PLX)

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.

Taliglucerase Alfa

Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company has commenced pre-clinical studies of an oral form of taliglucerase alfa. Its oral taliglucerase alfa is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity of the cell�� cellulose wall to protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active enzyme in the target organs; the spleen and liver. As of December 31, 2010, the Company had completed Phase III Clinical Trial.

PRX-102

The Company is developing PRX-102, its plant cell expressed modified version of the recombinant ! alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme. The Company is in the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.

Acetylcholinesterase

Protalix Ltd. is a wholly owned subsidiary of the Company is licensed the rights to certain technology under a research and license agreement with Yissum Research and Development Company (Yissum) and the Boyce Thompson Institute, Inc. Pursuant to the agreement, the Company is developing PRX-105, a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.

As of December 31, 2010, its in-vitro experiments of PRX-105 have shown that the acetylcholinesterase enzyme in its ProCellEx protein expression system demonstrates biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase expressed in its ProCellEx protein expression system was able to treat animals exposed to the nerve gas agent analogues, both when injected with its acetylcholinesterase product candidate immediately before exposure or when injected after exposure. In March 2010, it initiated a preliminary phase I clinical trial of PRX-105, which the Company completed in June 2010.

pr-antiTNF

pr-antiTNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. The Company has designed the antiTNF as pr-antiTNF. pr-antiTNF is a plant cell-expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), f! used to t! he Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and its in-vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.

The Company competes with Genzyme, Actelion, Crucell N.V., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.

Advisors' Opinion:
  • [By Maxx Chatsko]

    Industrial biotech isn't the only industry headed to Brazil. Protalix (NYSEMKT: PLX  ) entered into a technology transfer agreement with Brazil's Ministry of Health last week that will pay the company $280 million. The deal is big news for Protalix's first product, Elelyso/Uplyso, which was developed with partner Pfizer (NYSE: PFE  ) . The treatment is approved as an enzyme replacement therapy, or ERT, for adults with type 1 Gaucher disease, and it marks a huge step forward for the future of biomanufacturing. In the following video, Fool contributor Maxx Chatsko explains what this means for the product's commercialization and the adoption of Protalix's novel plant cell-based expression system for therapeutic proteins.

  • [By Keith Speights]

    Other investors might wish that Pfizer would use some of its cash to acquire a few smaller companies. Protalix BioTherapeutics (NYSEMKT: PLX  ) has been mentioned as one possible candidate. The two companies already partner together on Gaucher disease drug Elelyso. In February, Protalix spurred rumors that Pfizer could be interested in buying the company after it announced that it had engaged Citigroup to pursue a "broad array of strategic alternatives."

Top 10 Biotech Companies To Buy For 2014: DiaMedica Inc (DMA)

DiaMedica Inc. (DiaMedica) is a development-stage company. The Company is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. DiaMedica's compound, DM-199, is a recombinant human protein for the treatment of both Type I and Type II diabetes and their complications. DiaMedica is starting a Phase I/II clinical trial for DM-199. DM-199 is a recombinant human protein, which improves glucose control, protects beta cells through the expansion of a population of antigen-specific immunosuppressive cells (Tregs), and proliferates insulin producing beta cells through the activation of certain growth factors. The Company�� DM-204 is a G-protein-coupled receptor agonist (GPCR) monoclonal antibody to treat Type II diabetes and some of the associated complication's. activating a receptor resulted in insulin sensitivity, insulin secretion and vasodilation. Advisors' Opinion:
  • [By Richard Rhodes]

    Given this economic backdrop, and developing pressure on corporate revenues, margins, and earnings, we feel that risk is being misplaced at current levels.

    The 14-day and 40-day models are now overbought. Now, the 14-day and 40-day are peaking, which would certainly indicate a correction stands as the highest probability.

    The % of stocks above their 10-day moving average (dma) is at the 70%-level; still a major divergence with prices.

    The % of stocks above their 200-dma stands at 77%. The 87% level marked previous highs. The 50-dma/150-dma cross breakdown now confirms a larger correction. Bottoms form between 30%-40%.

    Overall, the risk-reward remains skewed to the downside, regardless of whether prices remain above trendline resistance, as our model group suggests a correction to the 110-day moving average, currently at S&P 1711.

    A clear breakdown at that level would accelerate the decline towards the wide 200-dma and 380-dma range, between 1657-1571.

Top 10 Biotech Companies To Buy For 2014: Actelion Ltd (ATLN.VX)

Actelion Ltd is a Swiss biopharmaceutical holding company that focuses on the discovery, development and commercialization of small molecule drugs. The Company has four approved drugs on the market: Tracleer, an oral dual endothelin receptor antagonist; Veletri, a prostanoid vasodilator; Ventavis, an inhaled formulation of iloprost, and Zavesca, an oral treatment for type 1 Gaucher disease. Furthermore, the Company has a number of compounds various stages of development. The Company operates through a number of worldwide subsidiaries, including Actelion Registration Ltd, which holds marketing authorizations for products marketed in the European Union; Actelion Clinical Research, Inc, engaged in clinical development on behalf of the Company's group; Actelion Re SA, providing insurance solutions for the Company's group and Actelion US Holding Company, engaged in the holding activities of the Company's United States-based units. In September 2013, it acquired Ceptaris Therapeutics, Inc. Advisors' Opinion:
  • [By Victor Selva]

    Forest Laboratories has a current ratio of 2.69% which is higher than the ones registered by Endo International Plc (ENDP), Valeant Pharmaceuticals International (VRX) and Cubist Pharmaceuticals Inc. (CBST). For investors looking for a higher ROE, Allergan Inc. (AGN) and Actelion Ltd. (ATLN.VX) are good options.

Top 10 Biotech Companies To Buy For 2014: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Advisors' Opinion:
  • [By Ben Levisohn]

    That would be Amgen (AMGN), which fell 1.4% today,� Biogen Idec (BIIB), which dropped 5.1%, Celgene�(CELG), which declined 2.1%, Gilead Sciences (GILD), which dropped 4%, Regeneron Pharmaceuticals (REGN), which fell 3.8%, and Alexion Pharmaceuticals (ALXN), which finished off 1.1%.

  • [By Mani]

    Celgene Corporation (NASDAQ:CELG) plans to release its third quarter financial results on�Oct.24�and will host a conference call and live audio webcast on the same day at�9 a.m. ET�to discuss the financial and operational performance.

  • [By Keith Speights]

    Celgene (NASDAQ: CELG  ) also seems likely to present a tough challenge should ibrutinib gain approval for MCL. Celgene should find out in June if its top drug Revlimid will be approved for MCL. There's no question in my mind about Celgene's capability to market Revlimid effectively for this new indication if the FDA gives a positive decision.